Motixafortide acetate
As of the edition of 20 October 2026, Motixafortide acetate is a protein: marketed, first approved in 2023 (US); acts on CXCR4; US protection ends in 2030.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2023
- Kind
- Protein
- Brand name
- Aphexda
- First approved
- 8 September 2023 (US)
- Approvals on record
- 1 in 1 region
- Holder of the most recent approval
- Ayrmid Pharma
US protection
US protection ends in 2030.
The last listed US exclusivity ends in 2030. The application that gives this date is held by Ayrmid Pharma.
This is the US only, and it is not the date generics or biosimilars can enter.
The exact date and the listings behind it
In the product2 listings count towards this date. The exact date and each listing are in the product.
See the exact date and the 2 listings behind itRequest access. Nothing is shown until you do.
Companies that need a new molecule because of this drug
1 company on route B because of this drug.
Companies on route B for this drug
In the product1 company is on route B because of Motixafortide acetate.
See the 1 company on route B for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| CXCR4 | C-X-C chemokine receptor type 4 | P61073 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Ayrmid Pharma | Acquired holder | 2025 to now |
| BioLineRx | Originator | 2023 to 2025 |